Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Interim CEO, COO & CFO | March 03, 2022 | March 04, 2022 |
| Vincerx Pharma, Inc.VINC · Entity 84409 | Director | August 24, 2022 | August 26, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date March 03, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,000 |
Reported balance
After 2022-03-03 transaction · row 1
1 source rowRow 1 · 2022-03-03 · Grant · Acquired 175,000 · Balance 265,000 F1: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant.
Vincerx Pharma, Inc.
Report date August 24, 2022 · Filed August 26, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,000 |
Ending reported balance
After 2022-08-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-24 · Purchase · Acquired 18,400 · Balance 28,400 F1: Represents a weighted average purchase price. Actual purchase prices ranged from $1.638 to $1.649 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated. Row 2 · 2022-08-25 · Purchase · Acquired 11,600 · Balance 40,000 F2: Represents a weighted average purchase price. Actual purchase prices ranged from $1.6499 to $1.65 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a weighted average purchase price. Actual purchase prices ranged from $1.638 to $1.649 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.
F2: Represents a weighted average purchase price. Actual purchase prices ranged from $1.6499 to $1.65 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2022 Filed Aug 26, 2022 16:06 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | PurchaseCommon Stock | 11,600 | $1.65 | $19,138.84 |
DisclosureSEC source: 0000899243-22-029840 · doc4.xml · nonDerivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F2 · price: Represents a weighted average purchase price. Actual purchase prices ranged from $1.6499 to $1.65 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated. Read SEC document |
| August 24, 2022 Filed Aug 26, 2022 16:06 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | PurchaseCommon Stock | 18,400 | $1.65 | $30,299.28 |
DisclosureSEC source: 0000899243-22-029840 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 F1 · price: Represents a weighted average purchase price. Actual purchase prices ranged from $1.638 to $1.649 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated. Read SEC document |
| May 26, 2022 Filed May 31, 2022 16:06 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000899243-22-020150 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests in full on the earlier of May 26, 2023, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 17:55 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016440 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Interim CEO, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 F1 · shares: Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 17:05 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001209191-22-001788 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 20:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001209191-21-064924 · doc4.xml · derivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,294 Underlying: Common Stock · 30,000 shares Expires 2028-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 20:17 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 30,000 | $2.23 | $66,900.00 |
DisclosureSEC source: 0001209191-21-064924 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 18:24 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,963 | $0.00 Strike: $54.85 | $0.00 |
DisclosureSEC source: 0001209191-21-059984 · doc4.xml · derivative · entry 3 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,037 Underlying: Common Stock · 4,963 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 18:24 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 4,963 | $98.50 | $488,855.50 |
DisclosureSEC source: 0001209191-21-059984 · doc4.xml · nonDerivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 18:24 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 4,963 | $54.85 | $272,220.55 |
DisclosureSEC source: 0001209191-21-059984 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · derivative · entry 9 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,294 Underlying: Common Stock · 30,000 shares Expires 2028-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 30,000 | $2.23 | $66,900.00 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 7 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · derivative · entry 8 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,294 Underlying: Common Stock · 22,000 shares Expires 2028-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 2,077 | $98.90 | $205,415.30 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 6 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,100 | $97.28 | $107,008.00 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 5 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,077 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.89 to $97.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 2,330 | $96.32 | $224,425.60 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 4 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,177 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.68 to $96.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 7,335 | $95.02 | $696,971.70 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 3 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,507 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.66 to $95.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 9,158 | $94.23 | $862,958.34 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,842 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.63 to $94.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 17:25 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 22,000 | $2.23 | $49,060.00 |
DisclosureSEC source: 0001209191-21-052277 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 18:59 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | PurchaseCommon Stock | 3,600 | $12.66 | $45,576.00 |
DisclosureSEC source: 0000899243-21-026816 · doc4.xml · nonDerivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · derivative · entry 8 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,294 Underlying: Common Stock · 30,000 shares Expires 2028-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. Read SEC document |
| June 30, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 30,000 | $2.23 | $66,900.00 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · nonDerivative · entry 6 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 18:59 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | PurchaseCommon Stock | 6,400 | $12.59 | $80,576.00 |
DisclosureSEC source: 0000899243-21-026816 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · derivative · entry 7 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,594 Underlying: Common Stock · 20,000 shares Expires 2028-11-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 1,044 | $56.16 | $58,631.04 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · nonDerivative · entry 5 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.73 to $56.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 4,153 | $55.11 | $228,871.83 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · nonDerivative · entry 4 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.66 to $55.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 7,079 | $54.13 | $383,186.27 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · nonDerivative · entry 3 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,197 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $54.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | SaleCommon Stock | 7,724 | $53.39 | $412,384.36 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · nonDerivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,276 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.64 to $53.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 17:46 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | Exercise / conversionCommon Stock | 20,000 | $2.23 | $44,600.00 |
DisclosureSEC source: 0001209191-21-044027 · doc4.xml · nonDerivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 14, 2021 17:23 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $16.34 | $0.00 |
DisclosureSEC source: 0000899243-21-019560 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-12 F1 · derivative.exercise_date: The option vests in full on the earlier of May 13, 2022, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 20:00 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $46.10 | $0.00 |
DisclosureSEC source: 0001209191-21-009920 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · COO & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the Option shall vest and become exercisable on each monthly anniversary of the vesting start date (and if there is no corresponding day, the last day of the month). Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 21:27 UTC | Vincerx Pharma, Inc. VINC · Entity 84409 | GrantStock Option (right to buy) · Derivative | 6,667 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-035394 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires 2030-12-23 F1 · derivative.exercise_date: The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 19:04 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063601 · doc4.xml · derivative · entry 2 LOWE CHRISTOPHER P. · CIK 0001376260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F2 · derivative.exercise_date: 50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 19:04 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $29.60 | $0.00 |
DisclosureSEC source: 0001209191-20-063601 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date. Read SEC document |
| May 14, 2020 Filed May 18, 2020 14:13 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $45.88 | $0.00 |
DisclosureSEC source: 0001209191-20-030020 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning March 29, 2020. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 18:09 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $54.85 | $0.00 |
DisclosureSEC source: 0001209191-20-008065 · doc4.xml · derivative · entry 1 LOWE CHRISTOPHER P. · CIK 0001376260 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest and become exercisable monthly over four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.